Annals of Oncology

Article	Citations
The enduring decision-making role of the surgeon in the multidisciplinary management of GIST	816
LBA13 Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP	772
O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gast	761
Important news on nutritional support in cancer patients – but some EFFORT is still ahead	703
Editorial Board	595
Table of Contents	587
130P Oxaliplatin immune-induced syndrome (OIIS): A potentially life-threatening complication in colorectal cancer (CRC) patients (pts)	572
Letter to the editor regarding ‘Misclassified confounders in the second interim analysis of the MAGNITUDE trial’ by P. Chen, M. Liu, G.Y. Li, F. Sun, T. Li	535
Editorial Board	524
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial	464
Long-term outcomes in the PRIMA trial: a closer look at progression-free survival and overall survival	373
Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms	365
Editorial Board	356
287P Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer	352
281P Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: A meta-analysis of ra	348
Table of Contents	345
329P Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy	335
373P Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) tre	330
244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”)	316
362P CYBERNEO trial: Update of results at 14 years of follow-up	300
331P miR-21 and miR-34a as biomarkers of radiotherapy skin adverse events in ductal carcinoma in situ	289
325P Impact of breast tumour location on axillary nodal involvement, chemotherapy use, and survival	285
299P Single-cell transcriptomic analysis reveals specific luminal and T cell subpopulations associated with response to neoadjuvant therapy in early-stage breast cancer	275
288P Prognostic factors in nonmetastatic HER2 ‘low’ & HER2 ‘negative’ breast cancer: Single institute experience	273
328P Frequency of radiotherapy-induced malignancies in Li-Fraumeni syndrome patients with early breast cancer and influence of the radiotherapy technique	260

291P Prognostic implications of HER2 gain in patients with HR+/HER2- breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)	257
LBA76 The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ram	254
2185TiP Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity	253
1876P Cancer stigma: How Tunisian patients perceive their cancer	252
1874P Beliefs about chemotherapy in Tunisian patients newly diagnosed with cancer	250
352TiP Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial	249
194P Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study	248
LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcome	246
197P Clinical benefit of HER2-targeted therapies versus prior chemotherapy in refractory HER2 expressing and mutant gastrointestinal malignancies	236
213P Unlocking cancer treatment opportunities by population-based advanced diagnostics in Norway	226
1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study	200
179P Molecular tumor board directed treatment for patients with advanced stage solid tumors: A case-control study	198
LBA22 Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: Results from the DISCO randomized trial	197
191P Novel approach to proficiency testing demonstrates wide gaps in biomarker quality for colon cancer treatment	193
1867P A cross-sectional examination of information disclosure and health literacy amongst patients with lymphoma	190
226P LongiBloodImmunoM: A multi-step analysis pipeline for longitudinal blood-based immunomonitoring for immunotherapy clinical trial	190
LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047	188
210P Lung tumour vascularity is a risk factor for survival in NSCLC patients undergoing surgery	186
649P The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)	185
1880P Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico	176
LBA91 TOMAS2: A randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (T+O) or trabectedin (T) in advanced, metastatic, or unresectable soft tissue sarcomas (STS)	167
1258P Does FDG PET-based radiomics have an added value for prediction of overall survival in non-small cell lung cancer?	162
196P Serum metabolomics to determine survival of immunotherapy for advanced non-small cell lung cancer: Metabolomic analysis based on two cohorts	159
LBA89 Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas	159
222P Therapeutic opportunities for porcupine inhibition in gastrointestinal cancer	158
LBA82 Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HE	157
1179P The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients	155
ESMO	153
LBA95 Anamorelin and weight gain in patients with advanced non-small cell lung cancer (NSCLC) and cachexia: Efficacy and safety in the multinational phase III SCALA program	153
LBA90 A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS-0415)	150
1138P Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity	149
1135P Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 2	149
1237P Design and validation of a custom next-generation sequencing panel in melanoma, glioma and gastrointestinal stromal tumor	147
1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhi	144
1082O Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)	143
1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma	143
1245P A lymph nodal staging assessment model for various histologic types of small intestinal tumors	141
1060P Balance of CD36+ and CD16+ monocytes controls TLR-mediated cytokine release syndrome and MHC-dependent antitumor responses in EpCAM CAR T cell therapy for gastrointestinal cancers	140
1149P Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment	135
1227P Novel in vivo photonics-immunoassay system, inPROBE, for the rapid detection of HER2 in breast cancer	134
1317MO Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)	132
1132P Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy	132
1124P IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy: A deep biomarker analysis	129
1142P Personalized decision making in cutaneous squamous cell carcinoma: Integrating a clinico-pathological model for absolute metastatic risk into the staging systems	126
1352P Plasma metabolic signatures uncover therapeutic response and prognosis of third-generation EGFR-TKI treatment in patients with NSCLC	125
1334P Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency	124
1122P Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?	122
1407P Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort	122
1364P ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)	118
1240P Multi-centric validation of an AI-based sTIL% scoring model for breast cancer H&E whole-slide images	118

1158P Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)	117
1232P Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification	112
1207O Beyond 100,000 genomes project: Whole genome sequencing for cancer patients within NHS Genomic Medicine Service	112
1456P Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)	111
1418P Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study	108
1642P Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients	106
1357P Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy	105
1398P Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)	103
1403P Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program	103
1488P Exploring efficacy and safety of immune checkpoint inhibitors (ICI) in extensive stage (ES)- small-cell lung cancer (SCLC) in specific populations: Real-world data from the Durvalumab Expanded A	102
1367P Predictive clinical characteristics for body weight gain in patients treated with alectinib: Analyses of J-ALEX, ALUR, and ML29453	100
1249P Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data	99
1462P Phase Ia study of MIDRIX4-LUNG, a quadrivalent autologous dendritic cell immunotherapy, in patients with metastatic non-small cell lung cancer	98
1354P Beyond the common mutation: Examining chemotherapy success in uncommon EGFR mutations	98
1387P Efficacy of first-line treatment options in advanced HER2-altered non-small cell lung cancer: A multi-center retrospective study	98
1868P Challenges for shared decision making in incurable cancer, with a focus on health literacy	96
135P The lymphocyte stability index (LSI) forms a pan-cancer peripheral biomarker for overall survival post initiation of immune checkpoint blockade (ICB)	95
375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors	95
139P The characteristics in Chinese NSCLC patients with different BRAF mutation classes	95
1205TiP Camrelizumab combined with EP/EC chemotherapy followed by camrelizumab plus apatinib for first-line therapy of advanced extrapulmonary neuroendocrine carcinoma: A prospective, single-arm, mult	94
166P Metabolomic prediction of breast cancer treatment toxicities	93
156P The association between fibrotic endotypes, determined by pre-treatment serum levels of collagen metabolites, and survival outcomes in patients with pancreatic cancer	93
225P Utility of next-generation sequencing (NGS) in patients with advanced cancer in a low-middle income country	92
1290TiP A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell	91
131O A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort	88
1112P Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial	87
1118P Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy	86
1073P Overcoming resistance to immunotherapy with FGFR inhibition in GU cancer models	86
1068P Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in melanoma and lung cancer models	86
1231P Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer	86
1430P Excellent performance of a fast and fully-automated RNA based genefusion assay conducted on a large fusion positive non-small cell lung cancer cohort within a multicenter study	84
1486P Treatment patterns and real-world clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era	83
1379P Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations	83
1350P Survival benefits of local treatment (LT) for brain metastases (BMs) in patients (pts) with EGFR-mutant non-small cell lung cancer (EGFR-mt NSCLC) treated with osimertinib	83
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET	82
742MO Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer	82
1469P The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer	82
Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors	80
698P Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendo	80
LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results	79
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM	77
Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey	76
LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the	75
CN59 A scoping review to establish the utility of patient reported outcome measures in blood cancer	75
854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC	74
LBA75 Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trial	73
14P Immunomodulatory effect of denosumab in early breast cancer: Preliminary results of a randomized window-opportunity clinical trial D-Biomark	73
Leveraging big data of immune checkpoint blockade response identifies novel potential targets	73
710MO Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial	73
834P Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO)	72
ESMO pays tribute to Professor José Baselga	72
SPARC macrophages in lymphoma	71
Table of Contents	71
Challenges of artificial intelligence in precision oncology: public-private partnerships including national health agencies as an asset to make it happen	71
The role of chemoradiotherapy in organ preservation for rectal cancer	71
Reply to the Letter to the Editor ‘Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?’ by Y. Sasaki; E. Sato & C. Sakaguchi	71
Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer	70
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third stud	70
PS3-5 Phase III study of palonosetron for preventing chemotherapy-induced nausea and vomiting in pediatric patients	69
138MO A randomized study to compare outcomes of intravesical chemohyperthermia with mitomycin C vs intravesical BCG for intermediate and high risk non-muscle invasive bladder cancer (NMIBC)	69
312TiP Impact of early palliative care integration on quality of life and symptom burden in patients with high-grade glioma	68
181P Pegylated liposomal doxorubicin (PLD) combined with docetaxel and trastuzumab in neoadjuvant treatment for HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial	68
SO-11 Response evaluation after neoadjuvant chemotherapy for resectable gastric cancer: Downsizing vs downstaging	68
919P Survival impact of nutritional status of locally advanced head and neck cancer squamous cell carcinoma (HNSCC) patients treated with chemoradiotherapy: A prospective observational study	67
918P Impact of locally advanced head and neck cancer treatment: Is there a role for exercise? FIT4TREAT	67
916P Impact of sarcopenia (S) on efficacy and toxicity of nivolumab (N) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study	67
922P Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting	66
321P A comprehensive predicting model of recurrence in stage III colon cancer from PETACC-8 trial	64
195P A prognostic signature based on two-miRNA and pathological data in early-stage HER2+ breast cancer patients	64
924P HANNA: Effectiveness and quality-of-life data from a real-world study of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab	64
O8-4 Siteless study for feasibility of electronic patient-reported outcome (ePRO) collection system in oncology	64
O3-4 Etoposide, doxorubicin, and cisplatin with mitotane in metastatic adrenocortical carcinoma in the National Cancer Center	64
185P Receipt of neoadjuvant treatment (NADJ) and impact of types of surgery on health-related quality of life (HRQoL) among patients (pts) with early stage HR+/HER2- breast cancer (BC)	63
O10-3 Selpercatinib (LOXO-292) in patients (pts) with RET-altered thyroid cancer	63
198P Complications associated with prolonged GCSF with dose-dense EC chemotherapy for early breast cancer patients	63
O14-3 End-of-life decision-making among the AYA cancer patients	62
O16-1 Association of self-perceived burden with symptoms among patients with cancer undergoing outpatient chemotherapy	62
O13-4 Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial	62
334P Adjuvant radiotherapy improves overall survival in patients with stage T4N0-2M0 sigmoid colon cancer	60
O17-1 Subcutaneous (SC) epcoritamab induces complete responses across R/R B-cell NHL subtypes: Updated dose-escalation data	60

83P Association of lung immune prognostic index (LIPI) with progression-free survival (PFS) in soft-tissue sarcoma (STS) patients treated with immunotherapy (IO) in early phase trials	59
213P Predictive markers of cardiotoxicity associated with breast cancer treatment	59
PD1-1-1 Phase Ib study of BI 836880 (VEGF/Ang2 nanobody®) plus ezabenlimab (BI 754091, anti-PD-1 antibody) in patients with solid tumors	59
PD3-1-3 Utility and role of multigene panel tests for patients with cancer: Retrospective data from a single institution	59
PD3-2-3 The short-time results of the OncoGuide NCC Oncopanel System for use in cancer genome profiling at a single institute	58
970P Assessment of anti-PD-1 antibody and immune complex binding to Fcγ receptors and clinical implications	58
342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients	58
89P Survival and immunotoxicity profiles in younger versus elderly patients with metastatic renal cell cancer undergoing immunotherapy	57
SO-22 Clinical classification-based evaluation of adjuvant therapy with oxaliplatin in stage II colon cancer	56
336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies	56
975P Impact of body mass index on the efficacy of immune checkpoint inhibitors in cancer	56
979P Efficacy of pembrolizumab with concomitant use of antibiotics	55
1246P Multicenter phase Ib/II study of second-line varlitinib and paclitaxel in patients with EGFR/HER2 co-expressing advanced gastric cancer (K-MASTER-13)	55
982P A phase II study of SHR-1701 plus famitinib for patients with previously treated advanced pancreatic cancer or biliary tract cancer	55
224P Value of bone scintigraphy in breast cancer patients staged with computed tomography	54
SO-30 Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma	54
44P Breast cancer subtypes in Georgia: Higher frequency of triple-negative breast cancer compared to resource-rich areas	54
1325P Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315)	54
45P Spatially-resolved single-cell HER2 tumor heterogeneity captured by biophysical modeling	52
1331P Open-label phase I/II study evaluating the tolerability and anti-tumor activity of selinexor (SEL) and docetaxel (DTX) in non-small cell lung cancer (NSCLC)	52
1328P Outcomes from local consolidative therapy and immune checkpoint inhibitors in metastatic non-small cell lung cancer	52
47P Immune tumor microenvironment and markers of apoptosis in breast cancer in carriers of hereditary mutations in the BRCA1 gene	51
1763P Real-world outcomes before and after the access to immune-checkpoint inhibitors (ICI) in advanced urothelial carcinoma (aUC)	51
1335P Updated results from a phase I/II study of anlotinib plus docetaxel vs docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC)	50
1337P Clinical study of apatinib combined with radiation therapy in advanced non-small cell lung cancer patients with brain metastasis	50
51P Novel platform combines pathology and transcriptomics for a multi-scale analysis and visualization of the breast tumor heterogeneity	50
877P Characteristics of malignant cutaneous adnexal tumors in a single-institution study	49
P-42 How to improve outcome in high-risk stage III colon cancer with dMMR gene	48
1340P The characteristics of the intestinal flora of advanced non-small cell lung cancer in China and its role in chemotherapy based on metagenomics	48
893P Autophagy flux is induced in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)	48
69P Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial	48
76P How to explain current reluctance against therapeutic de-escalation: Results of the exploratory qualitative phase of the mixed method research program CARTE therapy in older women with early breas	48
71P Aromatase inhibitors and fracture prevention: Is our current approach correct?	48
P-46 GIT carcinoids and the risk of multiple primary GIT tumors	47
901P Cisplatin vs carboplatin in extrapulmonary neuroendocrine carcinoma	46
P-47 Double-blind placebo-controlled randomized clinical trial on the concurrent use of crocin during chemoradiation of esophageal squamous cell carcinoma	46
84P Serum 25-hydroxyvitamin D and cancer-related fatigue: Associations and effects on health-related quality of life in breast cancer survivors during adjuvant endocrine therapy	46
273TiP ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treate	46
P-51 Epigenome-wide DNA methylation profiling identifies the TNXB gene as a potential epigenetic candidate for colorectal cancer prevention	46
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy	45
P-55 Obstructive gastric and gastroesophageal junction cancer predicts worse survival in curatively treated patients – analysis from a tertiary care center in India	44
18P Adoptive cell therapy (ACT) with bispecific gamma delta TCR+ invariant TCR+ NKT-like cells for multiple myeloma (MM): Comparison of preconditioning (PC) on outcome	44
16P Development of a 3D lung cancer model and evaluation of the efficiency of a human antibody directed against a novel target	44
1357P A deep radiomics approach to assess PD-L1 expression and clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A multicentric study	44
13P Berberine associated to SGLT2i dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to trastuzumab through induction of pAMPK and reduction of NLRP3 inflammasome, IL-6, met	44
1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian s	43
P-184 Demographic and clinicopathologic factors in patients with hepatocellular carcinoma in Latin American population	42
1037P Taxol-ramucirumab-pembrolizumab (TRP) for immuno-resistant/refractory NSCLC	42
1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI	41
LBA28 Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial	41
1044P Taxanes plus immunotherapy might be a potential option for HER2-altered NSCLC beyond first-line progression: A retrospective real-world study	41
224P Adherence to adjuvant hormonal therapy in patients with localized breast cancer	41
1039P Efficacy and safety of surufatinib (HMPL-012) as a third-line or further treatment for advanced non-small cell lung cancer (NSCLC)	41
1048P Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial	40
1046P Homologous recombination deficiency (HRD) and genomic associations in non-small cell lung cancer (NSCLC) using a novel HRD signature (HRDsig)	40
228P Association between chemotherapy toxicities and financial problems in the first three cycles of chemotherapy breast cancer patients	40
P-186 Efficacy of the combined chemotherapy regimens in elderly patients with advanced pancreatic cancer	39
227P Development of a novel free-to-use software for upper limb volume assessment in breast cancer related lymphedema: Integrating an augmented reality tool in the complex management of breast cancer	39
234P Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests	39
248P Axillary nodal involvement (ANI) predictive model by primary histopathological features in invasive breast cancer (IBC): A real-world analysis of 1,400 cases	38
238P Budget impact analysis for the health care package by using MammaPrint in Belgium	38
1057P Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced	38
1062P Predictive impact of inflammation scores in non-small cell lung cancer patients treated with immunotherapy rechallenge	38
239P Real-world evidence of comorbidities related to prognostic factors in European breast cancer patients	38
P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study	38
105P Pan-tumor survey of ROS1 fusions detected by next-generation RNA sequencing	38
P-202 Topical diclofenac in prevention of capecitabine-associated HFS in patients with GI cancers: An exploratory subgroup analysis of the D-ToRCH study	37
249P Significance of intraoperative frozen assessment of cavity shave margins in patients undergoing breast conservation surgery: A tertiary care centre experience	37
P-199 Comparison of treatment outcomes of regorafenib for patients with metastatic colorectal cancer by era: A propensity-score matched analysis	37
1076P Cancer cachexia associated with gut microbiota and clinical outcomes of patients with non-small cell lung cancer amenable to immunotherapy	37
126P The HLA I composite score and VHIO immune gene-expression signature (VIGex) as selection tools to explore the tumor microenvironment (TME) in patients (pts) treated with immunotherapy (IT)	36
Title Page	36
Acknowledgement	36
P-210 Efficacy and tolerability of cetuximab 750 mg/m2 every three weeks in metastatic colorectal cancer	36
142P Effectiveness and safety of pegylated liposomal doxorubicin- cyclophosphamide vs. epirubicin-cyclophosphamide as adjuvant chemotherapy for stage I and II HER2-negative breast cancer: An interim a	36
P-211 Factors predicting nodal spread in curatively resected gastric cancer – analysis from a tertiary care center in India	36
1083P The analysis molecular characteristics, PD-L1, TMB and MSI in Chinese NF1-mutated NSCLC	36
1081P DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients	36
1100P Association of clinical and molecular factors with immune checkpoint inhibitors efficacy in advanced non-small cell lung cancer: A systematic review and meta-analysis	35
1233P EGFR-TKIs compared with radiotherapy for patients of stage IV lung adenocarcinoma with EGFR mutation	35
LBA37 A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)	35
470P Genomic landscape and its correlations with immunotherapy-related biomarkers in Chinese colorectal cancer patients	35
LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated w	35
PSY5-3 Research policy for cancer dyspnea: Dyspnea at rest	34
SY01-1 Novel therapies and Immunotherapy for small cell lung cancer: Finally, some progress	33
481P Evaluation of serum mid-infrared spectroscopy as new prognostic marker for bevacizumab-based chemotherapy in first-line treatment of metastatic colorectal cancer	33
PSY8-1 Management of HBOC: from the view of genomic medicine	33
PSY8-2 HBOC – Molecular basis and its clinical implications	33
791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma	33
1235P Comparative study between two 17-gray fractions versus thirteen 39-gray fractions palliative thoracic radiotherapy in advanced non-small cell lung carcinoma	33
160P LungMetrics India: Molecular epidemiology and testing patterns in 4,773 non squamous NSCLC patients	33
1680P An activator of GPX4 protects against doxorubicin-induced cardiomyopathy	32
1242P Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study	32
SY02-3 Expectations of home-based exercise research for enhancing cancer survivorship care	32
162P A CT radiomics model to predict overall survival following curative-intent radiotherapy for stage I-III non-small cell lung cancer	32